Released Aug 15, 2022, after the close
10-Q filed Aug 15, 2022, 46 days after period end · 0001193125-22-221297
Q2 2022 · 10-Q
Revenue—
Net Income-$10.15M-$10.15M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.25-$0.25 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$10,411,000N/M
Operating Cash Flowderived-$6,468,000N/M
Free Cash Flowderived-$6,504,000—
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Net Income | -$10.15M | -$61.36M | -$2.04M |
| EPS Diluted | -$0.25 | -$141.93 | -$4.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR